

Comparisons of Non-Small Cell Lung Cancer Treatment Options:

*New Zealand and Australia versus
European Society for Medical Oncology (ESMO) Guidelines*


Version: 28th February 2020



TUAPAPA PŪKAHUKAHU
LUNG FOUNDATION
New Zealand

European Society for Medical Oncology (ESMO) treatment guidelines algorithm for non-small cell lung cancer (NSCLC) as at: 28 February 2020

Chemotherapy
targeted
Immunotherapy




NOTES: 1. lines of therapy not shown for ALK/BRAF/EGFR/ROS1
2. nivolumab/ipilimumab for TMB high included in guidelines but excluded here as registration file was withdrawn from EU

Source: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, *Annals of Oncology*, Volume 29, Issue Supplement_4, 1 October 2018, Pages iv192–iv237



TUAPAPA PŪKAHUKAHU
LUNG FOUNDATION
New Zealand

NZ publicly funded treatment options compared with ESMO Guidelines for NSCLC as at: 28 Feb 2020



Source: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, *Annals of Oncology*, Volume 29, Issue Supplement_4, 1 October 2018, Pages iv192–iv237.

1. Gandhi et al, Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer, NEJM 2018

Australian-publicly funded treatment options compared with ESMO Guidelines for NSCLC as at: 28 Feb 2020



NOTES: 1. lines of therapy not shown for ALK/BRAF/EGFR/ROS1
 2. nivolumab/ipilimumab for TMB high included in guidelines but excluded here as registration file was withdrawn from EU

Source: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, *Annals of Oncology*, Volume 29, Issue Supplement_4, 1 October 2018, Pages iv192–iv237


Australian publicly-funded NSCLC treatment options: as at 28 February 2020

Chemotherapy

targeted

Immunotherapy

1. Chemotherapy
2. Afatinib
3. Alectinib
4. Atezolizumab
5. Ceritinib
6. Crizotinib
7. Erlotinib
8. Gefitinib
9. Nivolumab
10. Pembrolizumab
11. Osimertinib
12. Durvalumab



Source: Australian Pharmaceutical Benefits Scheme

Note: Line of therapy not shown for ALK/EGFR


1. Scarpace SL. Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. *Drugs in Context*. 2015;4:212289. doi:10.7573/dic.212289.
2. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). *American Journal of Cancer Research*. 2015;5(9):2892-2911
3. Paul Hofman: ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice; *Cancers* 2017, 9, 107; doi:10.3390/cancers9080107
4. <https://www.pbs.gov.au/browse/medicine-listing?init> (accessed Jul 18)
5. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=atezolizumab> TECENTRIQ® Roche
6. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=nivolumab> OPDIVO® BMS
7. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=erlotinib> TARCEVA® Roche
8. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=gefitinib> IRESSA® Astra Zeneca
9. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=afatinib> GILOTRIF® Boehringer-Ingelheim – Not available in New Zealand
10. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=crizotinib> XALKOR® Pfizer
11. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=alectinib> ALECENSA® Roche
12. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=ceritinib> ZYKADIA® Novartis – Not available in New Zealand
13. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=Keytruda&=/> KEYTRUDA® MSD
14. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=osimertinib&=/TAGRISSO> Astra Zeneca
15. <https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/new-hope-for-lung-cancer-patients-with-ground-breaking-treatment-option-to-be-listed-on-the-pbs> Imfinzi® Astra Zeneca
16. Gandhi et al, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, *NEJM* 2018



TUAPAPA PŪKAHUKAHU
LUNG FOUNDATION
New Zealand

New Zealand publicly-funded⁴ NSCLC treatment options compared with Australia: as at 28 Feb 2020

1. Chemotherapy
2. Erlotinib
3. Gefitinib
4. Alectinib



Source: Australian Pharmaceutical Benefits Scheme

Note: Line of therapy not shown for ALK/EGFR

1. Scarpace SL. Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. *Drugs in Context*. 2015;4:212289. doi:10.7573/dic.212289.
2. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). *American Journal of Cancer Research*. 2015;5(9):2892-2911
3. Paul Hofman: ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice; *Cancers* 2017, 9, 107; doi:10.3390/cancers9080107
4. <https://www.pharmac.govt.nz/tools-resources/pharmaceutical-schedule/> (accessed Jul 18)
5. <http://www.medsafe.govt.nz/profs/Datasheet/t/tarcevatab.pdf> TARCEVA® Roche
6. <http://www.medsafe.govt.nz/profs/Datasheet/l/lressatab.pdf> IRESSA® Astra Zeneca
7. <https://www.medsafe.govt.nz/profs/Datasheet/a/alectensacap.pdf> Alecensa® Roche
8. Gandhi et al, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, *NEJM* 2018



TUAPAPA PŪKAHUKAHU
LUNG FOUNDATION
New Zealand

New Zealand publicly-funded⁴ NSCLC treatment options compared with Australia: as at 28 February 2020

